GlassScriptPhysician profile
Lori A Hill
NPI 1477938934
$11,025.36
in general payments reported to CMS, 2019-2025
50 companies · $2,989 in 2025
The $2,989 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $949 · 2022: $1,850 · 2023: $2,916 · 2024: $2,321 · 2025: $2,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,844 · Long Term Medical Supply Or Device Loan: $199 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,844.04 |
| Long Term Medical Supply Or Device Loan | $199.40 |
| Education | $182.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,803.68 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $1,393.93 | 2021-2025 | Tagrisso, Imfinzi, Lynparza |
| Genzyme Corporation | $524.54 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $504.10 | 2024-2025 | |
| Abbvie INC. | $444.41 | 2023-2025 | |
| Pfizer INC. | $413.87 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $359.19 | 2023-2024 | Libtayo |
| Gilead Sciences, INC. | $313.87 | 2023-2025 | Trodelvy |
| Daiichi Sankyo INC. | $307.38 | 2023-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $293.69 | 2022-2025 | Iclusig |
| Beigene USA, INC. | $285.04 | 2021-2024 | Brukinsa |
| Merck Sharp & Dohme LLC | $236.70 | 2024-2025 | Keytruda, Welireg |
| Jazz Pharmaceuticals INC. | $224.27 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $204.31 | 2021-2024 | Rezlidhia, Tavalisse |
| Exelixis INC. | $202.77 | 2022-2025 | Cabometyx |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $202.05 | 2023-2025 | Ojjaara |
| Amgen INC. | $197.85 | 2021-2023 | Kyprolis, Blincyto |
| Kite Pharma, INC. | $194.65 | 2022-2023 | |
| Janssen Biotech, INC. | $193.75 | 2023-2024 | Darzalex, Tecvayli, Rybrevant |
| Astellas Pharma US INC | $180.11 | 2024-2025 | Vyloy, Padcev |
| Eisai INC. | $174.63 | 2021-2024 | |
| Emd Serono, INC. | $157.86 | 2024-2025 | |
| Novocure INC. | $128.67 | 2025 | Optune Lua (Novottf-200t) |
| Incyte Corporation | $124.86 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Alnylam Pharmaceuticals INC. | $121.85 | 2021 | |
| Seagen INC. | $121.85 | 2023 | Padcev |
| Pharmacosmos Therapeutics INC. | $118.52 | 2023 | Monoferric |
| Syndax Pharmaceuticals, INC. | $116.33 | 2025 | Revuforj |
| Mirati Therapeutics, INC. | $112.65 | 2023 | Krazati |
| Blueprint Medicines Corporation | $108.79 | 2024 | Ayvakit |
| Lilly USA, LLC | $104.24 | 2022-2023 | Retevmo, Jaypirca, Verzenio |
| Pharmacyclics LLC, An Abbvie Company | $99.89 | 2022 | |
| Adaptive Biotechnologies Corporation | $96.17 | 2022 | |
| Servier Pharmaceuticals LLC | $83.77 | 2024 | |
| Sanofi-Aventis U.S. LLC | $83.00 | 2025 | |
| Tersera Therapeutics LLC | $82.29 | 2024-2025 | Zoladex |
| Taiho Oncology, INC. | $81.37 | 2022 | |
| Celgene Corporation | $81.12 | 2025 | Reblozyl |
| Aveo Pharmaceuticals, INC. | $71.18 | 2023-2024 | Fotivda |
| Abbott Laboratories | $71.14 | 2025 | Cardiomems |
| Stemline Therapeutics INC. | $67.13 | 2023 | Orserdu |
| Genentech, INC. | $62.35 | 2025 | Itovebi |
| Kyowa Kirin, INC. | $47.37 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $44.29 | 2025 | |
| Geron Corporation | $40.55 | 2025 | Rytelo |
| Bayer Healthcare Pharmaceuticals INC. | $39.28 | 2023 | |
| Puma Biotechnology, INC. | $38.51 | 2024 | |
| Alexion Pharmaceuticals, INC. | $26.38 | 2025 | Ultomiris |
| Sobi, INC | $22.75 | 2025 | |
| Genentech USA, INC. | $16.41 | 2025 | Tecentriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.